RBC Capital lowered the firm’s price target on Agilon Health to $23 from $28 and keeps an Outperform rating on the shares. The company’s Q3 results were “mixed” with revenue above consensus but medical margin 8% below the midpoint of prior guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGL: